Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00853970
Recruitment Status : Completed
First Posted : March 2, 2009
Results First Posted : January 26, 2011
Last Update Posted : January 25, 2013
Information provided by (Responsible Party):
Bausch & Lomb Incorporated

Brief Summary:
Efficacy study of Bromfenac Ophthalmic Solution in cataract surgery

Condition or disease Intervention/treatment Phase
Pain Inflammation Drug: Bromfenac Ophthalmic Solution Drug: Placebo Comparator Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 299 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : February 2009
Actual Primary Completion Date : September 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: Bromfenac ophthalmic solution 0.09%
dosed 1 drop daily in study eye for 2 weeks
Drug: Bromfenac Ophthalmic Solution
sterile ophthalmic solution

Placebo Comparator: Placebo
dosed 1 drop daily in study eye for 2 weeks
Drug: Placebo Comparator
sterile ophthalmic solution

Primary Outcome Measures :
  1. Summed Ocular Inflammation Score (SOIS) of Zero [ Time Frame: Day 15 (Primary Endpoint) ]
    Participants with SOIS of 0. Measured on a scale of 0-4: 0=0 cells (complete absence); 0.5=1-5 cells ; 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=>50 cells (intense)

Secondary Outcome Measures :
  1. Pain Free [ Time Frame: Day 1 ]
    Participants that are pain free at day 1, taken from patient questionnaire with multiple possible responses measured on a scale of 0-3, where 0=none and 3=severe.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female at least 18 years of age who are scheduled for unilateral cataract surgery

Exclusion Criteria:

  • Have known hypersensitivity to bromfenac or to any component of the investigational product

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00853970

United States, California
ISTA Pharmaceuticals, Inc.
Irvine, California, United States, 92618
Sponsors and Collaborators
Bausch & Lomb Incorporated
Study Director: Tim McNamara, PharmD ISTA Pharmaceuticals, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bausch & Lomb Incorporated Identifier: NCT00853970     History of Changes
Other Study ID Numbers: CL-S&E-1205081-P
First Posted: March 2, 2009    Key Record Dates
Results First Posted: January 26, 2011
Last Update Posted: January 25, 2013
Last Verified: January 2013

Keywords provided by Bausch & Lomb Incorporated:
Pain and Inflammation as a function of cataract surgery

Additional relevant MeSH terms:
Pathologic Processes
Pharmaceutical Solutions
Ophthalmic Solutions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents